Get access

Significant responses to platinum-based chemotherapy in renal medullary carcinoma

Authors

  • John J. Strouse MD,

    Corresponding author
    1. Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    2. Division of Pediatric Hematology, John Hopkins University School of Medicine, Baltimore, Maryland
    • Division of Pediatric Hematology, Ross Building Room 1125, 720 Rutland Avenue, Baltimore, MD 21205.
    Search for more papers by this author
  • Melissa Spevak MD,

    1. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • A. Kyle Mack MD,

    1. Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    2. Division of Pediatric Hematology, John Hopkins University School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • Robert J. Arceci MD, PhD,

    1. Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Search for more papers by this author
  • Donald Small MD, PhD,

    1. Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Search for more papers by this author
  • David M. Loeb MD, PhD

    1. Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Search for more papers by this author

Abstract

Most patients with renal medullary carcinoma (RMC) have advanced disease at presentation and rarely respond to radiation or chemotherapy. We describe two adolescents with metastatic disease who had significant responses to cisplatin or carboplatin in combination with gemcitabine and paclitaxel. © 2004 Wiley-Liss, Inc.

Get access to the full text of this article

Ancillary